Enveric Biosciences
ENVB
9 hedge funds and large institutions have $3.42M invested in Enveric Biosciences in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
2,274% more capital invested
Capital invested by funds: $144K → $3.42M (+$3.27M)
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
200% more funds holding
Funds holding: 3 → 9 (+6)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$664K |
| 3 |
VF
Virtu Financial
New York
|
+$664K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$245K |
| 5 |
EGM
Engineers Gate Manager
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$43K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $1.73M | +$2.2M | +63 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $556K | +$664K | +19 | +1,900% |
|
|
VF
3
Virtu Financial
New York
| $556K | +$664K | +19 | +1,900% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $193K | +$245K | +7 | New |
|
|
EGM
5
Engineers Gate Manager
New York
| $120K | +$140K | +4 | New |
|
6
UBS Group
Zurich,
Switzerland
| $97K | +$105K | +3 | New |
|
7
Bank of New York Mellon
New York
| $65K | +$69.9K | +2 | New |
|
|
SSA
8
Schonfeld Strategic Advisors
New York
| $62K | +$69.9K | +2 | New |
|
9
Northern Trust
Chicago,
Illinois
| $34K | +$34.9K | +1 | New |
|
10
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$43K | -1 | Closed |
|
ENVB Hedge Fund Activity: Q1 2021 in Review
9 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q1 2021, worth a combined $3.42M — up 2,274% from $144K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ENVB positions and 1 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.2M. The largest seller was Citadel Advisors, exiting entirely with an estimated $43K sold.
- 9 institutional investors held Enveric Biosciences (ENVB) as of Q1 2021, up from 3 in Q4 2020.
- Funds reported $3.42M of Enveric Biosciences stock for Q1 2021, up 2,274% quarter-over-quarter.
- 7 funds opened new Enveric Biosciences positions in Q1 2021 and 1 closed out, a net change of +6 holders.
- The largest Enveric Biosciences buyer in Q1 2021 was BlackRock, an estimated $2.2M added.
- The largest Enveric Biosciences seller in Q1 2021 was Citadel Advisors, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2021.